Tuesday, BMO Capital maintained its Outperform rating and $67.00 price target on Silence Therapeutics (NASDAQ:SLN), despite the stock's recent significant decline. Silence Therapeutics' shares fell over 35%, contrasting with the flat performance of the XBI biotech index, following updates from the American Heart Association (AHA). Concerns have emerged that favorable data for Muvalaplin, an oral medication, may pose a competitive threat to Silence Therapeutics' Zerlasiran or might diminish pharmaceutical companies' interest in forming partnerships.
The analyst from BMO Capital believes the market's reaction to the news is excessive. The firm sees no safety issues or competitive threats from the new data, noting the potential in the Lp(a) market, which is estimated to be worth more than $20 billion. The analyst's confidence in Zerlasiran remains unshaken by the recent downturn.
On the same day, Silence Therapeutics' management reaffirmed their confidence in Zerlasiran and their commitment to securing a partnership. While the absence of a partnership continues to weigh on the company, BMO Capital views the current lower stock price as an opportunity for investors to buy the dip.
The market's concerns stem from two main factors: the potential impact of Muvalaplin on Zerlasiran's market prospects and questions regarding Zerlasiran's safety profile. Despite these concerns, BMO Capital's analysis suggests that the underlying fundamentals of Silence Therapeutics remain strong.
Investors are closely watching Silence Therapeutics as the company navigates the competitive landscape and seeks to establish strategic partnerships. The reaffirmation by company management and the continued support from BMO Capital may contribute to shaping market perception in the near term.
In other recent news, Silence Therapeutics has been making significant strides in the biotechnology sector with its drug development programs. The company reported positive trial results for its lead siRNA candidate, which has shown significant efficacy in lowering Lp(a), a causal risk factor for cardiovascular disease, by more than 90%. Jefferies has initiated coverage on the company's stock with a Buy rating, highlighting the potential of this candidate and its less frequent injections compared to similar programs.
Furthermore, Silence Therapeutics' second candidate for treating Polycythemia Vera, a hematologic disease, has demonstrated promising Phase 1 data. This has prompted H.C. Wainwright and BMO Capital Markets to maintain their Buy and Outperform ratings respectively.
In addition to these developments, Silence Therapeutics received a $2.0 million milestone payment from Hansoh Pharmaceutical (TADAWUL:2070) Group Company Limited, marking the second milestone in their partnership to develop short interfering RNAs. The company also announced the retirement of board member Alistair Gray, yet maintains a robust financial position with over $200 million expected to last into 2026.
InvestingPro Insights
Recent InvestingPro data provides additional context to Silence Therapeutics' (NASDAQ:SLN) current situation. The company's market capitalization stands at $335.07 million, reflecting the recent stock price decline. This decline is evident in the stark -32.02% 1-week price total return and -38.74% 1-month price total return, aligning with the article's mention of the stock's significant drop following the AHA updates.
InvestingPro Tips highlight that SLN's stock is currently in oversold territory based on its RSI, which could support BMO Capital's view that the market's reaction might be excessive. Additionally, the tip indicating that SLN holds more cash than debt on its balance sheet suggests financial stability, potentially providing the company with flexibility as it seeks partnerships and advances its pipeline.
It's worth noting that analysts anticipate a sales decline and a drop in net income for the current year, which investors should consider alongside the optimistic outlook presented by BMO Capital. For a more comprehensive analysis, InvestingPro offers 11 additional tips for Silence Therapeutics, providing investors with a broader perspective on the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.